Do you want to read an article? Please log in or register.
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis
Inflammatory Bowel Disease
Related content
Hepatology
Refining the Baveno VII criteria for clinically significant portal hypertension: an individual-patient data meta-analysis
J Hepatol
Bañares J, Pons M, Reiberger T, Mandorfer M, Jachs M, Semmler G, Colecchia A, Colecchia L, Dajti E, Bureau C, Larrue H, Grgurević I, Kujundžić PD, Fortea JI, Puente A, Berzigotti A, Tsochatzis E, Bosch J, Abraldes JG, Genesca J, a study by the Baveno Cooperation: an EASL consortium
doi: 10.1016/j.jhep.2025.10.014
Hepatology
Endovascular interventions reduce rebleeding in patients with gastric varices: An individual patient data meta-analysis
Clin Gastroenterol Hepatol
Biswas S, Aggarwal A, Lo GH, Luo X, Yang L, Escorsell A, Mehta S, Swaroop S, Agarwal S, Agarwal A, Saxena S, Mishra AK, Tripathi S, Gunjan D, Gamanagatti S, Shalimar
doi: 10.1016/j.cgh.2026.01.002
Gastrointestinal Cancer
Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis
Eur J Cancer
Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N, Hasegawa K, Matsuyama Y, Nishioka Y, Aparicio T, Guimbaud R, Malicot KL, Tu D, O'Callaghan C, Lutz MP, Fontana E, Moehler M, Mauer ME, Sclafani F
doi: 10.1016/j.ejca.2025.116092
RECOMMENDED
Inflammatory Bowel Disease
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG
doi: 10.1016/S2468-1253(25)00129-3
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
RECOMMENDED
Inflammatory Bowel Disease
Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis
Sul HH, Gewehr DM, Kang H, Junior OR, Ungaro RC, Bernstein CN
doi: 10.1093/ecco-jcc/jjaf202
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036
Inflammatory Bowel Disease
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
J Crohns Colitis
Colombel JF, Wu J, Kobayashi T, Zhu B, Paulissen J, Dhanabal A, Jairath V, Siegel C, Siegmund B, Redondo I, Moses R, Magro F
doi: 10.1093/ecco-jcc/jjaf124
Inflammatory Bowel Disease
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol
Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group
doi: 10.1016/S2468-1253(25)00322-X